Kiromic BioPharma Inc. (KRBP)
AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Kiromic BioPharma Statistics
Share Statistics
Kiromic BioPharma has 1.55M shares outstanding. The number of shares has increased by 20% in one year.
Shares Outstanding | 1.55M |
Shares Change (YoY) | n/a |
Shares Change (QoQ) | 0% |
Owned by Institutions (%) | n/a |
Shares Floating | 1.13M |
Failed to Deliver (FTD) Shares | 659 |
FTD / Avg. Volume | 49.85% |
Short Selling Information
The latest short interest is 45.74K, so 2.96% of the outstanding shares have been sold short.
Short Interest | 45.74K |
Short % of Shares Out | 2.96% |
Short % of Float | 4.06% |
Short Ratio (days to cover) | 1.45 |
Valuation Ratios
The PE ratio is -0.04 and the forward PE ratio is -0.63.
PE Ratio | -0.04 |
Forward PE | -0.63 |
PS Ratio | 0 |
Forward PS | null |
PB Ratio | -0.1 |
P/FCF Ratio | -0.04 |
PEG Ratio | n/a |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Kiromic BioPharma Inc..
EV / Earnings | n/a |
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.22, with a Debt / Equity ratio of -1.7.
Current Ratio | 0.22 |
Quick Ratio | 0.22 |
Debt / Equity | -1.7 |
Total Debt / Capitalization | 242.03 |
Cash Flow / Debt | -1.37 |
Interest Coverage | 10.77 |
Financial Efficiency
Return on equity (ROE) is 2.33% and return on capital (ROIC) is -310.5%.
Return on Equity (ROE) | 2.33% |
Return on Assets (ROA) | -1.75% |
Return on Capital (ROIC) | -310.5% |
Revenue Per Employee | 0 |
Profits Per Employee | -608.40K |
Employee Count | 35 |
Asset Turnover | 0 |
Inventory Turnover | 0 |
Taxes
Income Tax | 0 |
Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -56.45% in the last 52 weeks. The beta is 1.98, so Kiromic BioPharma 's price volatility has been higher than the market average.
Beta | 1.98 |
52-Week Price Change | -56.45% |
50-Day Moving Average | 0.97 |
200-Day Moving Average | 1.82 |
Relative Strength Index (RSI) | 39.72 |
Average Volume (20 Days) | 1.32K |
Income Statement
Revenue | n/a |
Gross Profit | -2.80M |
Operating Income | -19.94M |
Net Income | -21.29M |
EBITDA | -16.30M |
EBIT | n/a |
Earnings Per Share (EPS) | -21.41 |
Balance Sheet
The company has 3.20M in cash and 15.54M in debt, giving a net cash position of -12.34M.
Cash & Cash Equivalents | 3.20M |
Total Debt | 15.54M |
Net Cash | -12.34M |
Retained Earnings | -122.90M |
Total Assets | 10.24M |
Working Capital | -14.83M |
Cash Flow
In the last 12 months, operating cash flow was -21.23M and capital expenditures -206.60K, giving a free cash flow of -21.43M.
Operating Cash Flow | -21.23M |
Capital Expenditures | -206.60K |
Free Cash Flow | -21.43M |
FCF Per Share | -19.53 |
Margins
Gross Margin | n/a |
Operating Margin | n/a |
Pretax Margin | n/a |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | n/a |
Dividends & Yields
KRBP does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Payout Ratio | n/a |
Earnings Yield | -2460.92% |
FCF Yield | -1593.51% |
Analyst Forecast
Currently there are no analyst rating for KRBP.
Price Target | n/a |
Price Target Difference | n/a |
Analyst Consensus | n/a |
Analyst Count | n/a |
Stock Splits
The last stock split was on Mar 13, 2023. It was a backward split with a ratio of 1:30.
Last Split Date | Mar 13, 2023 |
Split Type | backward |
Split Ratio | 1:30 |
Scores
Altman Z-Score | -28.2 |
Piotroski F-Score | 1 |